SAN FRANCISCO, April 06, 2018 -- Hagens Berman Sobol Shapiro LLP reminds investors in MiMedx Group, Inc. (NASDAQ:MDXG) of the April 25, 2018 Lead Plaintiff deadline in the pending securities class action. If you purchased or otherwise acquired securities of MiMedx between March 7, 2013 and February 21, 2018 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/MDXG
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing
On February 20, 2018, MiMedx postponed release of its fourth quarter and fiscal year 2017 financial results. Defendants explained “[t]he Audit Committee of MiMedx’s Board of Directors has engaged independent legal and accounting advisors to conduct an internal investigation into current and prior-period matters relating to allegations regarding certain sales and distribution practices at the Company” and “Company executives are also reviewing, among other items, the accounting treatment of certain distributor contracts[.]”
This news drove the price of MiMedx shares down $5.72, or nearly 40%, to close at $8.75 on February 20, 2018.
Then, Reuters reported federal authorities are investigating whether MiMedx overcharged the government for its tissue-repair products and whether it improperly booked sales of products that hadn’t been ordered, a practice known as channel stuffing.
“We’re focused on Defendants’ previous denials of improper accounting that, if false, damaged investors and on whether MiMedx submitted false claims to the Federal government,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding MiMedx should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 70+ attorneys in 11 offices across the country. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 510-725-3000


PayPal Shares Sink as $50 Billion Takeover Bid Collapses
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation
Yindjibarndi Appeals Fortescue Mining Compensation Ruling
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’
Amazon Secures 200 MW Wind Power Deals in Sweden
Google Changes EU Spam Policy Amid Antitrust Scrutiny
Street Poller Media and The Boom of the Street Interview Ad Industry
Trump Administration Plans New Drug Pricing Deals With Biotech Firms
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook
Itochu Offers $1.56 Billion to Privatize Dentsu Soken
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim
Mercer International Stock Surges 45% on C$20 Million Canada Funding
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules
OpenAI AI Agent Swarm Behind Hugging Face Hack
Toyota Global Sales Fall as China Demand Slumps 



